短期瑞舒伐他汀干预对ACS患者血浆TM、hsCRP水平的影响

目的检测急性冠脉综合征(ACS)患者血浆血栓调节蛋白(TM)及高敏C反应蛋白(hsCRP)在未调脂治疗前及使用10mg/d瑞舒伐他汀治疗7天后水平的变化。方法选择ACS患者32例及非冠心病患者16例为对照组;治疗组入选者在调脂治疗前和治疗7天后清晨空腹分别抽取静脉血,对照组入院次晨空腹抽取静脉血。采用酶联免疫吸附法定量测定TM及hsCRP。结果 ACS患者治疗前血浆TM及hsCRP水平均明显高于正常对照组患者血浆TM及hsCRP;瑞舒伐他汀治疗组短期治疗后,TM及hsCRP水平均比治疗前明显降低,差异均有统计学意义。结论 ACS患者血浆TM和hsCRP均升高;早期强化他汀药物治疗能降低血浆TM及hsCRP水平。

The Effects of Rosuvastatin Intervence on Plasma Thrombomodulin and High Sensitive C-reactive Protein in Patients with Acute Coronary Syndrome

Objective To observed the variations of plasma thrombomodulin（TM） and high sensitive C- reactive protein（hsCRP） levels in the patients with acute coronary syndrome（ACS） in before statins treatment and used rosuvastatin （10mg/d） after 7 days. Methods 32 patients with ACS were enrolled therapy groups and 16 persons were selected as a control group who excepted coronary heart disease through coronary arteriongraphy. The levels of plasma TM and hsCRP were measured before treatment and after 7 days by rosuvastatin＇ s therapy respectively in rosuvastatin therapy groups. And they were measured only before treatment in control group. The levels of TM and hsCRP were measured by sandwich assay enzyme linked immunosorhent assay（ELISA）. Results The levels of TM and hsCRP in all of the patients with ACS before therapy were higher significantly than those in control group. In rosuvastatin therapy groups, the levels of TM and hsCRP after therapy were decreased significantly than those before therapy. Conclusions The levels of TM and hsCRP will be increase in the patients with ACS. High dose statins intervence in early stage of ACS can decease the level of TM and hsCRP.